The FDA slapped a clinical hold on Achillion Pharmaceuticals Inc.'s hepatitis C virus (HCV) drug sovaprevir after elevations in liver enzymes turned up in a Phase I trial, though the agency will allow continued enrollment and treatment of patients in the ongoing Phase II trial of sovaprevir with ACH-3102 and ribavirin for treatment-naive genotype 1 HCV.